How organoids can improve personalized treatment in patients with gastro-esophageal tumors.
Curr Opin Pharmacol
; 69: 102348, 2023 04.
Article
en En
| MEDLINE
| ID: mdl-36842387
ABSTRACT
Gastro-esophageal tumors constitute a big health problem. Treatment options still mainly rely on chemotherapy, and apart from human epidermal growth factor receptor 2 positive and microsatellite instable/Epstein-Barr Virus disease, there are no molecularly guided options. Therefore, despite the large number of identified molecular alterations, precision medicine is still far from the clinic. In this context, the recently developed technology of patient-derived organoids (PDOs) could offer the chance to accelerate drug development and biomarker discovery. Indeed, PDOs are 3D primary cultures that were shown to reproduce patient's tumor characteristics. Moreover, several reports indicated that PDOs can replicate patient's response to a given drug; therefore, they are one of the most promising tools for functional precision medicine.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Esofágicas
/
Infecciones por Virus de Epstein-Barr
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Curr Opin Pharmacol
Asunto de la revista:
FARMACOLOGIA
Año:
2023
Tipo del documento:
Article
País de afiliación:
España